摘要
目的:评价促红细胞生成素在危重患者贫血治疗中的效果及安全性。方法:将62例危重患者随机分为EPO组(32例),入院后注射重组促红细胞生成素(rhEPO)150U/kg,持续9d;对照组(30例),入院后未用rhEPO。结果:两组患者的RET计数和Hb的恢复差异明显,有统计学意义(P<0.05)。结论:危重患者贫血在早期使用rhEPO后,可以提高RET计数,Hb含量增加,可有效改善患者的贫血。
Objective. To evaluate the effect and safety of erythropoietin on critically ill patients with anemia. Methods： 62 cases of critically ill patients were randomly divided into the EPO group （32 cases） and the control group （30 cases）. Patients in the EPO group were injected with 150 U/kg recombinant erythropoietin （rhEPO） for 9 consecutive days after being admitted into the hospital while 30 patients in the control group were not injected with rhEPO. Results： Theree were significant differences of the KET counts and the rehabilitation of Hb between the patients in both groups （P〈0.05）. Conclusion： Patients with severe anemia treated with rhEPO at the earlier stage can increase the RET counts and the concentration of Hb, and effectively improve the comditions of patients with anemia.
出处
《华夏医学》
CAS
2013年第3期492-494,共3页
Acta Medicinae Sinica
关键词
促红细胞生成素
危重患者
贫血
erythropoietin
critically-ill patients
anemia
